Breast Cancer Research
Whether you have early stage breast cancer or metastatic breast cancer, research can play an important role in your treatment plan, offering you access to leading-edge treatments. It can also play an important role in other peoples’ lives. By participating in a breast cancer clinical trial, you help pave the way to new prevention, detection and treatment strategies that can offer hope to people with cancer.
As an academic medical center, we are involved in some of the most groundbreaking cancer trials available today. By choosing the USC Breast Center for your breast care, you have access to clinical trials that are helping make breast cancer a disease of the past.
- Breast cancer breakthroughs
- Breast cancer clinical trials
- Finding a cure
- Improving detection, treatment, prevention
- National Cancer Institute (NCI) designation
- Understanding breast cancer causes
What our National Cancer Institute designation means
In 1973, USC Norris Comprehensive Cancer Center was designated as one of the country’s original eight comprehensive cancer centers by the National Cancer Institute (NCI), the federal government’s principle agency for cancer research and training. As an NCI-designated cancer center, we anchor the country’s cancer research efforts, making scientific discoveries that are translated into new treatments for people with cancer. The collective work of NCI researchers has led to important medical advances that have increased the number of cancer survivors in the United States and worldwide.
USC Norris cancer research breakthroughs
Our clinician-scientists have been at the forefront of cancer research for more than 40 years, making historic breakthroughs that have changed the way we understand breast cancer and how it’s treated.
Combined Breast MRI/Biomarker Strategies to Identify Aggressive Biology
PRIMARY OBJECTIVES: I. To determine the number of high risk women with abnormal screening breast MRI and morphologically normal biopsy over 7 years. SECONDARY OBJECTIVES: I. To determine if WNT10B/ ...Learn More ≫
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
PRIMARY OBJECTIVES: I. To determine if 3-year recurrence-free survival (RFS) is greater than 92% among clinical stages II or IIIa patients with HER2-positive breast cancer who achieve ...Learn More ≫
Core Biopsies of Breast Tumor Tissue Repository
PRIMARY OBJECTIVES: I. To develop a baseline and serial breast cancer core biopsy repository within the University of Southern California (USC)/Norris Comprehensive Cancer Center Women's Cancer Program. II. ...Learn More ≫
FDG PET to Assess Therapeutic Response in Patients With Bone-Dominant Metastatic Breast Cancer, FEATURE
PRIMARY OBJECTIVE: I. Evaluate the performance of fludeoxyglucose F-18 (FDG)-positron emission tomography (PET)/computed tomography (CT) response criteria (modified PET Response Criteria in Solid Tumors [PERCIST] complete, partial ...Learn More ≫
I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)
I-SPY will compare the efficacy of novel drugs in combination with standard chemotherapy with the efficacy of standard therapy alone. The goal is identify improved treatment regimens for subsets ...Learn More ≫